吡格列酮和罗格列酮治疗老年2型糖尿病的疗效对比(英文) 被引量：2

Comparison of clinical effects between rosiglitazone and pioglitazone in the treatment of type 2 diabetes of eldly patients

暂未订购

导出

摘要目的探讨吡格列酮和罗格列酮对2型糖尿病患者血糖、血脂水平的影响。方法将我院内分泌科门诊及病房收治的符合1997年WHO诊断标准的2型糖尿病患者64例。予以饮食控制,运动治疗,且同时口服降糖药物固定在1mo以上,空腹血糖仍≥7 mmol·L^(-1)的患者,随机分为吡格列酮组和罗格列酮组,分别加用吡格列酮或罗格列酮12 wk。结果①吡格列酮组和罗格列酮组的空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数均较治疗前明显降低(P<0.05),两者之间降低的程度没有显著性差异。②吡格列酮组血三酰甘油和总胆固醇水平较治疗前明显降低(P<0.05),但罗格列酮组无明显变化(P>0.05)。③2组的高密度脂蛋白水平均比治疗前明显升高(P<0.05和P<0.01),但吡格列酮组升高的幅度大于罗格列酮组。结论吡格列酮和罗格列酮治疗后均能有效控制血糖,但吡格列酮能更明显地改善血脂。 AIM To compare the clinical effects of rosiglitazone with pioglitazone in the treatment of type 2 diabetic patients. METHODS Sixty-four patients who had been treated with food control, exercise and fixed oral anti-diabetic drugs for one month, but their fasting plasma glucose level was still over 7 mmol·L^-1. They were randomized divided into two groups . One was added with rosiglitazone, the other was added with pioglitazone. All of them were treated for 12 weeks. RESULTS After treatment for 12 weeks, （1）patient＇s fasting plasma glucose, postprandial plasma glucose, HbA1c and insulin resistance index were significant decreased in both groups; （2）triglyeeride and total cholesterol were decreased in pioglitazone group（ P 〈 0.05） ,but those in rosiglitazone group were no significant reduction（ P 〉 0.05） ;（3） high density lipoprotein-cholesterol was elevated in both groups（ P 〈 0.05）. CONCLUSION Rosiglitazonc or pioglitazone can be used to control blood glucose, but pioglitazone shows more efficiency on triglyceride control.

作者顾芹陈芳蒋翠萍孙皎

机构地区复旦大学附属华东医院内分泌科

出处《中国临床药学杂志》 CAS 2008年第5期259-261,共3页 Chinese Journal of Clinical Pharmacy

关键词 2型糖尿病罗格列酮吡格列酮 type 2 diabetes meUitus rosiglitazone pioglitazone

分类号 R587.1 [医药卫生—内分泌] R977.15 [医药卫生—药品]

引文网络
相关文献

参考文献5

1Yonemitsu S, Nishimura H, Shintani M, et al. Troglitazone induces GLUT4 translocation in L6 myotubes[J]. Diabetes,2001,50(5) : 1093.
2Parulkar AA, Pendergras ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones[J]. Ann Intern Med, 2001, 134(1) : 60.
3吴坚,邹大进,吴文君.国产吡格列酮对2型糖尿病患者的疗效及安全性研究[J].中国新药杂志,2002,11(5):399-400. 被引量：5
4Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients v, ith type 2 diabetes and dyslipidemia[J]. Diabetes Care,2005,28(7) : 1547.
5Gillies PS, Dunn CJ. Pioglitazone[ J ]. Drugs, 2000,60(2 ) : 333.

二级参考文献6

1[1]Smith SA,Cawthorne MA,Coyle PJ,et al.BRL 49653 normalises glycaemic control in Zucker fa/fa rats by improving hepatic and peripheral tissue sensitivity to insulin[J].Diabetologia,1993,36(1)∶184.
2[2]Oakes ND,Kennedy CJ,Jenkins AB,et al.A new antidiabetic agent,BRL 49653,reduces lipid availability and improves insulin action and glucoregulation in the rat[J].Diabetes,1994,43∶1203-1210.
3[3]Bloomgarden ZT.Insulin resistance:current concepts[J].Clin Ther,1998,20∶215-216.
4[4]Saltidel AR,Olefsky JM.Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes[J].Diabetes,1996,45∶1661-1667.
5[5]Spiegelman BM. PPARγ adipogenic regulator and thiazolidinedione receptor[J].Diabetes,1998,47∶507-514.
6[6]Young PW,Cawthorne MA,Coyle PJ,et al.Repeat treatment of obese mice with BRL 49653,a new potent insulin sensitizer,enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling[J].Diabetes,1995,44∶1087-1092.